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Background: Phosphodiesterase-4 (PDE4) inhibitors have potential utility as a new therapeutic
approach to improving symptoms and pulmonary function in asthma and COPD. This study evaluated
the efficacy and safety of MK-0359, a selective and potent oral PDE4 inhibitor, in chronic asthma.
Methods: Adults (NZ 88) with1 year asthma history and an FEV1 50e80% predicted were random-
ized to double-blind treatment with MK-0359 (15 mg/day) or placebo for 14 days, then crossed-over
to the other treatment for 14 days. The primary endpoint was the change from baseline in FEV1 at
the end of each 2-week treatment period. Secondary and other endpoints included the changes
from baseline in Daytime asthma symptom score, Nighttime asthma symptom score, Total daily
b-agonist use (puffs/day), AM and PM peak expiratory flow (PEF) and overall asthma-specific
quality-of-life. Safety and tolerability were assessed by clinical adverse experiences.
Results: MK-0359 significantly improved the primary endpoint (versus placebo): the least-squares
mean difference in change from baseline in FEV1 (L) was 0.09 L (95% CI 0.01, 0.18). Endpoints of
Daytime asthma symptom score, Nighttime asthma symptom score, Total daily b-agonist use, AM
PEF, PM PEF, and quality-of-life were also significantly improved. Nineteen patients (24.1%) on
MK-0359 and 8 patients (10.4%) on placebo reported gastrointestinal clinical adverse experiences.
Serious gastrointestinal clinical adverse experiences were reported in 3 patients while receiving
MK-0359.
Conclusion: Over a 14-day treatment period, the oral PDE4 inhibitor MK-0359 improved lower airway
function, symptoms and rescue medication use in chronic asthma, although at the expense of
gastrointestinal adverse experiences. (Clinical trial registry number: NCT00482898.)
ª 2008 Elsevier Ltd. All rights reserved.2 594 5464; fax: þ1 732 594 5195.
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Despite the availability of several controller agents, asthma
remains poorly controlled in many patients, and its preva-
lence continues to be unacceptably high.1,2 Thus, there is
much interest in exploring alternative therapeutic
approaches that target further pathways mediating lower
airway function.3 Phosphodiesterase (PDE) consists of
a family of enzymes that hydrolyze cAMP, an ubiquitous
mediator that regulates several cellular processes. The
enzymes PDE4A, PDE4B, and PDE4D are expressed in
inflammatory cells such as T cells, B cells, eosinophils,
neutrophils, and airway epithelial and endothelial cells.4
Several studies in animal models and in patients with
asthma or COPD have demonstrated that the selective
inhibition of PDE4 produces relaxation of smooth muscle
and inhibition of cellular inflammatory processes.3e5 The
PDE4 inhibitors roflumilast and cilomilast have been
reported to improve pulmonary function and symptoms in
asthma and COPD patients.6e8
Recently, the compound MK-0359 was reported to be
a potent and selective PDE4 inhibitor with in vivo efficacy in
animal models of asthma.9 MK-0359 preferentially inhibited
the hydrolysis of cAMP by PDE4A, 4B, and 4D, significantly
reversed bronchoconstriction in ovalbumin-sensitized and
challenged guinea pigs, and blocked late airway response in
ascaris-sensitized and challenged sheep.9 In previous Phase
I studies, a range of doses of MK-0359 up to 20 mg in healthy
subjects was generally well-tolerated (unpublished data). A
14-day, double-blind, placebo-controlled safety study of 12
patients (8 treated with MK-0359 15 mg/day and 4 with
placebo) showed that the drug was generally well-toler-
ated. The frequencies of gastrointestinal adverse experi-
ences of nausea, emesis (vomiting), loose stool, loss of
appetite, and abdominal cramping in preliminary, blinded
data were each 1/12 (8%).
Based on these studies, a 15-mg dose was expected to
provide a level of systemic drug exposure (area under the
curve of approximately 3367 nM h) less than the no-
observed-effect-level (the highest dose at which no effects
can be observed, a measure of chronic toxicity) for emesis
seen in animal studies. Dose-dependent and sustained (up
to 24 h) ex vivo inhibition of lipopolysaccharide-stimulated
TNF-a, a surrogate marker for the anti-inflammatory
activity of PDE4 inhibitors, was seen in a single-dose phar-
macodynamic study evaluating doses up to 40 mg of MK-
0359 in healthy subjects (unpublished data). Furthermore,
in a multiple-dose study evaluating daily doses of 0.25 mg,
2.5 mg, 5 mg, 10 mg, and 15-mg MK-0359 in healthy
subjects, the latter dose produced the greatest peak and
trough levels of ex vivo inhibition of lipopolysaccharide-
stimulated TNF-a (unpublished data). For these reasons, we
chose an MK-0359 dose of 15 mg/day for evaluating its
efficacy on FEV1 and other endpoints in patients with
chronic asthma, and for evaluating its safety and
tolerability.
Methods
This was a multicenter (26 study sites), randomized,
placebo-controlled, double-blind, crossover Phase II study(Protocol 013) conducted between September 2002 and
April 2003. Period I was a 14-day, single-blind, placebo run-
in period. Period II was a 14-day, double-blind, active-
treatment period where patients were allocated according
to a computer-generated, randomization schedule to either
MK-0359 15 mg/day or placebo. Period III was a 13-day
wash-out period. Period IV was a 14-day double-blind
treatment period where patients were crossed-over to the
other treatment.
Adult patients (NZ 88) with a clinical history of asthma
symptoms for 1 year, an FEV1 of 50e80% of predicted,
airflow reversibility of 12%, and a minimum pre-
determined level of daytime asthma symptoms and of
b-agonist use were enrolled. They were allowed the use of
as-needed short-acting b-agonist during the study;
approximately half the patients were allowed the use of
inhaled corticosteroids (ICS) at a stable dose.
Baseline values were established in the placebo run-in
period (Period I). The primary efficacy endpoint was the
change from baseline in FEV1 at the end of a once-daily
dosing interval, assessed at the end of each 2-week treat-
ment period (Periods II and IV). FEV1 was also measured at 2
and 4 h after the first dose, and at 2 and 4 h after the last
dose during the 2 weeks of treatment. Secondary endpoints
recorded daily10 were the changes from baseline in Daytime
asthma symptom score (a 4-item questionnaire assessing
frequency and level of symptoms and activity), Nighttime
asthma symptoms score (assessing awakenings), Total daily
b-agonist use (number of puffs), AM PEF, and PM PEF, each
assessed as the average of the last 7 days of treatment. The
changes from baseline in Asthma Quality of Life Question-
naire (AQLQ) domains (activity, emotion, symptoms, envi-
ronment)11 and in the average of all domains were assessed
after 2 weeks of treatment.
Changes from baseline in FEV1 were analyzed using an
analysis of variance model that contained factors for
sequence, patient within sequence, period, and treatment.
Other efficacy measurements were analyzed using a similar
model.
Safety and tolerabilitywere assessed by clinical evaluations
(physical examinations), adverse experience monitoring
(includingpotentialmechanism-basedgastrointestinaleffects,
with colitis identified as an adverse experience of special
interest), and laboratory safety tests.
The study was designed such that a sample size of 100
patients had approximately 80% power to detect (aZ 0.05,
two-sided) a 0.12 L between-treatment difference in
change from baseline in FEV1. However, because the study
was prematurely terminated (as described below), the final
sample size was smaller than planned.
The study was approved by an ethical review committee
or institutional review board for each study site. Informed
consent was obtained from each patient.Results
Forty-two patients were randomized to the MK-0359/
placebo arm and 46 patients to the placebo/MK-0359 arm
(Fig. 1). Fifty-six patients completed the study; 21 patients
discontinued. While this study was ongoing, MK-0359 failed
to achieve an overall acceptable benefit/risk ratio in
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Figure 1 Patient disposition. ySite terminated as described
in Results.
344 S. Lu et al.a concurrent study of COPD (Protocol 016). For this reason,
a decision was made to halt the development of MK-0359
for chronic lower airway disease. Therefore, the present
study was terminated, resulting in the discontinuation of
a further 11 patients. Reasons for discontinuation of these
32 patients are listed in Fig. 1.
Baseline characteristics were generally comparable
between the two treatment sequences (Table 1). Over the
treatment period, statistically significant effects of MK-
0359 over placebo were seen with the primary endpoint
(Table 2). Fig. 2 shows the mean change (L) from baseline inTable 1 Baseline characteristics of patients.
Patient
characteristics
Sequence
MK-0359/
placebo
(NZ 42)
Sequence
placebo/
MK-0359
(NZ 46)
Age, years
(range)
30.4 8.1
(18e43)
31.9 7.8
(18e44)
Sex, n (%)
Male 25 (59.5) 26 (56.5)
Race, n (%)
Asian 1 (2.4) 1 (2.2)
Black 4 (9.5) 4 (8.7)
Hispanic 2 (4.8) 3 (6.5)
White 34 (81.0) 38 (82.6)
Multi-race 1 (2.4) 0 (0.0)
Baseline FEV1 (L) 2.55 0.47 2.52 0.63
Baseline percent
predicted FEV1 (%)
64.6 8.18 64.7 9.16
Patients on inhaled
corticosteroid, n (%)
11 (26.2) 19 (41.3)
Unless otherwise specified, values are mean SD.FEV1 during the course of the study. Significant effects of
MK-0359 over placebo were also seen with the other
endpoints of Daytime and Nighttime asthma symptom
scores, Total daily b-agonist use, AM and PM PEF, overall
asthma-specific quality-of-life score, and total peripheral
blood eosinophil counts (Table 2). There were no acute
treatment effects immediately after dosing, as measured
by FEV1 at 2 and 4 h postdose (data not shown). There was
no evidence that patients on ICS (NZ 30) had a consistently
greater treatment effect than those not on ICS (NZ 58) in
the endpoints studied. For instance, for the primary
endpoint of FEV1, the difference between the treatment
groups in percentage change from baseline was 0.4% in
patients on ICS, and 5.9% in patients not on ICS.
The numbers of patients with clinical adverse experi-
ences are summarized in Table 3. Clinical adverse experi-
ences occurred in 62.0% of patients while receiving MK-0359
and 40.3% while receiving placebo. Nineteen patients
(24.1%) on MK-0359 and 8 patients (10.4%) on placebo
reported gastrointestinal clinical adverse experiences.
Serious clinical adverse experiences were reported in 3
patients while receiving MK-0359: abdominal pain (2) and
diarrhea (2). Four patients receiving MK-0359 were dis-
continued due to clinical adverse experiences determined
by the investigator to be drug related: vomiting (1), loose
stools (2), dizziness (3), paresthesia (1), and flushing (1).Discussion
Reduction in airway inflammation and relief from bron-
choconstriction are essential goals of current treatment
guidelines for asthma.12 The involvement of the PDE4
family of enzymes in cellular inflammation and broncho-
constriction offers a rationale for targeting them in asthma
therapy. The promising efficacy of PDE4 inhibitors in airway
disease has been reported by several investigators. Roflu-
milast produced dose-dependent improvement in FEV1 and
AM PEF in asthmatic patients, and both roflumilast and
cilomilast attenuated exercise-induced bronchocon-
striction.4,7 Cilomilast has, in general, shown an inconsis-
tent effect on bronchodilation in COPD studies.6
The results of the present study show that over a 14-day
treatment period, MK-0359 (15 mg/day) improved airway
function as measured by FEV1 at the end of the dosing
interval, as well as AM and PM PEF. The overall treatment
effect was significant, although modest: the average
improvement in change from baseline (MK-0359 minus
placebo) in FEV1 was about 3.5%, and the average
improvements in AM and PM PEF were 1.8e2.4%.
Significant improvements in asthma symptoms
throughout the day were seen, as measured by daytime
symptoms (average improvement [MK-0359 minus placebo]
in change from baseline was 9%) and nighttime symptoms.
Total daily b-agonist use is a useful clinical measure of the
control of symptoms,12 and the administration of MK-0359
resulted in a greater control when compared to placebo
(average improvement was 14.8%). Patients also reported
improved asthma-specific quality-of-life with MK-0359: the
total AQLQ score and the individual domains of symptoms
and activity were significantly improved versus placebo.
Taken together, these results are indicative of a significant
Table 2 Efficacy results.
Efficacy endpoints N Baseline
(mean)
LS mean
change from baseline
Treatment difference
(LS mean (95% CI))
MK-0359 Placebo
FEV1 (L) 62 2.58 0.14 0.05 0.09 (0.01, 0.18)*
Daytime asthma symptom score 67 2.34 2.05 2.26 0.21 (0.33, 0.09)***
Nighttime asthma symptom score 66 0.51 0.38 0.46 0.08 (0.16, 0.00)*
Total daily b-Agonist use (puffs/day) 66 4.74 3.92 4.61 0.70 (1.12, 0.27)**
AM PEF (L/min) 66 407.43 415.53 408.03 7.50 (0.98, 14.03)*
PM PEF (L/min) 67 425.30 436.86 426.85 10.01 (2.85, 17.17)**
AQLQa total score
(all domains score)
57 4.52 0.42 0.24 0.18 (0.00, 0.36)*
AQLQ activity domain score 57 4.85 0.43 0.21 0.22 (0.02, 0.41)*
AQLQ emotion domain score 57 4.38 0.34 0.29 0.04 (0.19, 0.28)
AQLQ symptom domain score 57 4.29 0.46 0.24 0.21 (0.02, 0.41)*
AQLQ environment domain score 57 4.54 0.43 0.23 0.20 (0.03, 0.43)
Total peripheral
blood eosinophil count (103/mL)
66 0.30 0.04 0.01 0.05 (0.08, 0.02)**
*p 0.05; **p 0.01; ***p 0.001.
a Asthma Quality of Life Questionnaire.
A selective PDE4 inhibitor for asthma 345efficacy of MK-0359 in asthma. Furthermore, an anti-
inflammatory effect of MK-0359 was suggested by the
reduction in blood eosinophil count, a marker of allergic
airway inflammation.13,14 Nevertheless, these results must
be interpreted with caution because the smaller sample
size resulting from the early termination of the study may
have reduced the possibility of showing significant effects
in some of our endpoints. The clinical significance of our
efficacy results in this Phase II study needs to be verified in
a longer-term and larger clinical trial.
In asthma patients, the inflammatory mediator TNF-a is
present in increased concentrations in mucosal biopsies and-0.10
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Figure 2 Mean change (Lbronchoalveolar fluid and is expressed in increased amounts
by airway mast cells; furthermore, recent studies have
proposed a role for this cytokine in severe asthma.15e17
PDE4 inhibition by MK-0359 in stimulated whole human
blood has been shown to effectively inhibit the production
of TNF-a.9
It remains to be demonstrated if inhibition of TNF-a
occurs in parallel with a demonstrated improvement
in airflow and symptoms in asthmatics treated with
MK-0359.
Several studies have called into question the utility of
the currently available PDE4 inhibitors as a class becauseWashout Period 1
Period IV
2
Period IV
) from baseline in FEV1.
Table 3 Number of patients with at least one clinical adverse experience (AE)a while on MK-0359 or on placebo.
Number (%) of patients MK-0359 (NZ 79) Placebo (NZ 77)
n (%) n (%)
With one or more AEs 49 (62.0) 31 (40.3)*
With drug-relatedb AEs 24 (30.4) 13 (16.9)*
With serious AEs 3c (3.8) 0
With serious drug-relatedb AEs 0 0
Who died 0 0
Discontinued due to an AE 6 (7.6) 3 (3.9)
Discontinued due to a drug-relatedb AE 4d (5.1) 0
Discontinued due to a serious AE 0 0
Discontinued due to a serious
drug-relatedb AE
0 0
*p< 0.05 for difference between groups.
a Includes all patients who received at least 1 dose of study medication.
b Determined by the investigator to be possibly, probably, or definitely drug-related.
c Abdominal pain (2 patients) and diarrhea (1).
d Vomiting (1 patient), loose stools (2), dizziness (3), parathesia (1), and flushing (1).
346 S. Lu et al.of their side effects. Headaches and gastrointestinal
disturbances such as diarrhea, nausea and vomiting were
some of the major side effects of roflumilast and cilomilast
in clinical studies of asthma and COPD.4,3 In our study, an
increase in the incidence of gastrointestinal adverse
experiences was seen with MK-0359; as with other available
PDE4 inhibitors, these side effects may limit the application
of this compound in clinical practice. It has been suggested
that the use of inhalation forms of PDE4 inhibitors may
overcome such effects.18 Furthermore, the therapeutic
ratio with respect to nausea and vomiting may be a function
of PDE4 subtype selectivity, and selective PDE4 inhibitors
that target specific PDE4 enzymes (such as PDE4B) may
alleviate adverse effects while still preserving the anti-
inflammatory effect of the inhibitor.3
Conclusion
Over a 14-day treatment period, the PDE4 inhibitor MK-0359
demonstrated significant, although modest, efficacy in
asthmatic patients, as measured by improvements in lower
airway function, symptoms, and rescue medication use.
Nevertheless, its poor tolerability profile appears to limit
its overall benefit as a new therapy in asthma.
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